A Phase I Study of RMC-6236 in People with Advanced Solid Tumors Containing Specific KRAS Mutations


Full Title

A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS


The purpose of this study is to find the highest dose of the investigational drug RMC-6236 that can be given safely in people with advanced solid tumors containing mutations in the KRAS gene. RMC-6236 targets the KRAS protein made by the mutated gene. The KRAS protein sends signals that cause cancer cells to grow. RMC-6236 is designed to prevent the KRAS protein from sending these signals, and this blocking action may slow or stop the growth of cancer cells. RMC-6236 is taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have a solid tumor that spread or continued to grow despite prior treatment.
  • Patients’ tumors must contain one of these KRAS mutations: KRAS G12A, G12D, G12V, G12R, or G12S. 
  • The serious side effects of previous therapies must go away before the study treatment is given.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people age 18 and older.


For more information and to ask about eligibility for this study, please contact the office of Dr. Kathryn Arbour at 646-608-3792.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID